| Specialty | GLP-1 / weight loss (mass-market telehealth) |
|---|---|
| Medications | Brand GLP-1s and compounded GLP-1s (from earlier profiles; not re-read) |
| Price | Not re-read: hims.com returned HTTP 403 to our reads on November 20, 2026, so Hims & Hers is not scored this round. |
| Read status | Not re-read: HTTP 403 on November 20, 2026 |
| Score | Not scored: hims.com returned HTTP 403 to our reads on November 20, 2026 |
| Website | hims.com |
What its filings and FDA’s index show
Hims & Hers’ quarterly report for the period ended September 30, 2026 says it filed a motion to dismiss the July 29, 2026 complaint by the FTC, the Utah Division of Consumer Protection and Los Angeles County on October 22, 2026, with a hearing currently set for January 14, 2027, and that it had accrued about $60 million for the matter. The complaint concerns subscription, cancellation and privacy practices; it is unresolved and its allegations are not findings. On November 6, 2026 Lilly and Hims announced that Hims patients can buy Zepbound and Foundayo at Lilly’s self-pay prices, from $299 and $149 a month. FDA’s warning-letter index lists letters dated September 9, 2025 to Hims & Hers Health, Inc. doing business as Hims (716567) and as Hers (716825).
What we could and could not verify
hims.com returned HTTP 403 to our reads on October 15 and again on November 20, 2026, so we have not confirmed Hims & Hers’s current prices, care model or pharmacy, and we do not score it. Earlier figures from our May 2026 profile have been removed rather than shown as current. Check the program’s own pricing page before you enroll.
Five checks before you enroll
- The prescriber. Look up the clinician’s name in the NPPES NPI Registry and on your state medical or nursing board site.
- The pharmacy. Ask which pharmacy fills the prescription and check its license with your state board of pharmacy (FDA’s BeSafeRx links to each board).
- The 12-month total. Add the program or membership fee, the medication at your expected maintenance dose and shipping, then multiply by 12 (by 13 for 28-day cycles).
- The exit terms. Read the cancellation and refund rules before the first charge.
- The drug itself. Ask whether you will get an FDA-approved brand product or a compounded preparation. Compounded semaglutide and tirzepatide are not FDA-approved and are not generics.
How Hims & Hers compares with NexLife
NexLife, the highest-scoring GLP-1 program at 86/100 on the v4.1 methodology, publishes compounded semaglutide at $95 a month and tirzepatide at $115 a month on 12-month plans ($109 and $129 month to month), the same price at every dose with no membership. It lost points for an open FDA warning letter (730096, June 8, 2026) and for conflicting price, state and pharmacy statements on its own pages. Price check: month to month, Mondae lists $126 for tirzepatide and $87 for semaglutide, and Eden Health $99 for semaglutide (read November 20, 2026). Our NexLife vs Hims & Hers comparison sets the two side by side.
Related reading
Sources
- hims.com (returned HTTP 403 on November 20, 2026), read November 20, 2026.
- Hims & Hers Form 10-Q for the quarter ended September 30, 2026 (SEC, filed November 9, 2026), read November 20, 2026.
- Lilly and Hims & Hers release (November 6, 2026), read November 20, 2026.
- FDA warning letter 716567 to Hims & Hers Health, Inc. dba Hims (September 9, 2025), read November 20, 2026.
- Our v4.1 scoring guide, published November 20, 2026.
GLP-1 program scores use the v4.1 methodology and pages read November 20, 2026; peptide and hormone clinics keep their May 2026 profiles and are not part of that ranking.